Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential

Inclusion Criteria

• •Age \>18 years;
• •Histological diagnosis of NSCLC
• •metastatic disease
• •Availability, at the time of enrollment, of adequate biological material to be able to perform molecular analyses, taken (surgical or by biopsy) before administration of any anti-tumor treatment (chemotherapy and/or radiotherapy);
• •ECOG PS 0-2;
• •Adequate hematological, hepatic and renal function;
• •Measurable disease according to RECIST criteria
• •Availability of follow-up data for at least 6 months and/or until death/progression
• •Age \>18 years;
• •Histological diagnosis of NSCLC
• •metastatic disease
• •Availability, at the time of enrollment, of adequate biological material to be able to perform molecular analyses, taken (during surgery and/or by biopsy) before administration of any anti-tumor treatment (chemotherapy and/or radiotherapy);
• •ECOG PS 0-2;
• •Adequate hematological, hepatic and renal function;
• •Measurable disease according to RECIST criteria;
• •Written informed consent (participation in the study and data processing)